Recordati Industria Chimica e Farmaceutica Yönetim
Yönetim kriter kontrolleri 4/4
Şu anda CEO hakkında yeterli bilgiye sahip değiliz.
Anahtar bilgiler
Rob Koremans
İcra Kurulu Başkanı
€2.5m
Toplam tazminat
| CEO maaş yüzdesi | 23.6% |
| CEO görev süresi | 2.9yrs |
| CEO sahipliği | n/a |
| Yönetim ortalama görev süresi | 4.2yrs |
| Yönetim Kurulu ortalama görev süresi | 5.2yrs |
Son yönetim güncellemeleri
Recent updates
We Like The Quality Of Recordati Industria Chimica e Farmaceutica's (BIT:REC) Earnings
Nov 18
Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Due To Pay A Dividend Of €0.60
Nov 14Earnings Beat: Recordati Industria Chimica e Farmaceutica S.p.A. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Nov 13Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Not Flying Under The Radar
Oct 31Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Sep 07We Think Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Stay On Top Of Its Debt
Aug 20Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 31% And Analysts Are Revising Their Forecasts
Aug 02Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Business Is Yet to Catch Up With Its Share Price
Aug 01Estimating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
May 26Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.63
May 10Recordati Industria Chimica e Farmaceutica's (BIT:REC) Dividend Will Be Increased To €0.63
Apr 25Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Share Price Could Signal Some Risk
Apr 23If EPS Growth Is Important To You, Recordati Industria Chimica e Farmaceutica (BIT:REC) Presents An Opportunity
Apr 08Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.63
Mar 23Is Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 27We Think Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Stay On Top Of Its Debt
Jan 09Risks To Shareholder Returns Are Elevated At These Prices For Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Dec 22Recordati Industria Chimica e Farmaceutica (BIT:REC) Has Announced That It Will Be Increasing Its Dividend To €0.57
Nov 12Is Recordati Industria Chimica e Farmaceutica (BIT:REC) Using Too Much Debt?
Sep 29Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Sep 08Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly
Jun 23Does This Valuation Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Imply Investors Are Overpaying?
Jun 05Recordati Industria Chimica e Farmaceutica's (BIT:REC) Conservative Accounting Might Explain Soft Earnings
Apr 08Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.60
Apr 05Recordati Industria Chimica e Farmaceutica (BIT:REC) Has Announced That It Will Be Increasing Its Dividend To €0.60
Mar 19Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly
Mar 06A Look At The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Dec 23Is Recordati Industria Chimica e Farmaceutica (BIT:REC) A Risky Investment?
Dec 05Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.55
Nov 11Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Intrinsic Value Is Potentially 42% Above Its Share Price
Sep 01These 4 Measures Indicate That Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Using Debt Reasonably Well
Aug 07An Intrinsic Calculation For Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Suggests It's 25% Undervalued
Jun 03Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Paying Out A Larger Dividend Than Last Year
May 16Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Paying Out A Larger Dividend Than Last Year
May 02Recordati Industria Chimica e Farmaceutica's (BIT:REC) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 18Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.57
Apr 04Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.57
Mar 21These 4 Measures Indicate That Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Using Debt Reasonably Well
Mar 06Calculating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Dec 22Recordati Industria Chimica e Farmaceutica (BIT:REC) Has A Pretty Healthy Balance Sheet
Dec 05Estimating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Sep 23Is Recordati Industria Chimica e Farmaceutica (BIT:REC) A Risky Investment?
Sep 05A Look At The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Jun 25Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly
Jun 07Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 8.5% And Analysts Are Revising Their Forecasts
May 10Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Shares Could Be 34% Above Their Intrinsic Value Estimate
Mar 11Here's What You Should Know About Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) 2.4% Dividend Yield
Feb 19Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Jan 30CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | €423m |
| Jun 30 2024 | n/a | n/a | €387m |
| Mar 31 2024 | n/a | n/a | €389m |
| Dec 31 2023 | €2m | €590k | €389m |
| Sep 30 2023 | n/a | n/a | €375m |
| Jun 30 2023 | n/a | n/a | €389m |
| Mar 31 2023 | n/a | n/a | €340m |
| Dec 31 2022 | €2m | €590k | €312m |
| Sep 30 2022 | n/a | n/a | €331m |
| Jun 30 2022 | n/a | n/a | €330m |
| Mar 31 2022 | n/a | n/a | €393m |
| Dec 31 2021 | €154k | n/a | €386m |
Tazminat ve Piyasa: Rob 'ın toplam tazminatı ($USD 2.62M ) Italian pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 3.22M ).
Tazminat ve Kazançlar: Rob 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Rob Koremans (62 yo)
2.9yrs
Görev süresi
€2,498,000
Tazminat
Dr. Robert Koremans, also known as Rob, M.D. serves as Chief Executive Officer and Director of Recordati Industria Chimica e Farmaceutica S.p.A. since December 1, 2021. Dr. Koremans served as Chief Executi...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 2.9yrs | €2.50m | Veri yok | |
| Group CFO & Executive Director | 5yrs | €1.23m | Veri yok | |
| Executive Director | no data | Veri yok | Veri yok | |
| Executive Director | 5.8yrs | Veri yok | Veri yok | |
| Executive Director | 4.6yrs | Veri yok | Veri yok | |
| VP & Head of Investor Relations | less than a year | Veri yok | Veri yok | |
| Group Chief Legal Officer | 1.6yrs | Veri yok | Veri yok | |
| Group Communications Director | no data | Veri yok | Veri yok | |
| Executive VP of Corporate Development | 8.2yrs | Veri yok | Veri yok | |
| Group Chief People & Culture Officer | less than a year | Veri yok | Veri yok | |
| Chief Medical Officer | 5.8yrs | Veri yok | Veri yok | |
| Executive Vice President of Specialty & Primary Care Business Unit | 3.8yrs | Veri yok | Veri yok |
4.2yrs
Ortalama Görev Süresi
55yo
Ortalama Yaş
Deneyimli Yönetim: REC 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.2 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 2.9yrs | €2.50m | Veri yok | |
| Group CFO & Executive Director | 2.8yrs | €1.23m | Veri yok | |
| Executive Director | 5.9yrs | Veri yok | Veri yok | |
| Executive Director | 5.9yrs | Veri yok | Veri yok | |
| Executive Director | 4.6yrs | Veri yok | Veri yok | |
| Non-Executive Chairman | 26.6yrs | €315.00k | Veri yok | |
| Independent Non-Executive Director | 4.6yrs | €80.00k | Veri yok | |
| Lead Independent Director | 10.6yrs | €103.00k | Veri yok | |
| Independent Director | 2.8yrs | €90.00k | Veri yok | |
| Chairman of Statutory Auditor Board | 7.6yrs | Veri yok | Veri yok | |
| Independent Non-Executive Director | 5.8yrs | €85.00k | Veri yok | |
| Non-Executive Vice Chairman | 4.6yrs | €90.00k | Veri yok |
5.2yrs
Ortalama Görev Süresi
54.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: REC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.2 yıldır).